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Human artificial chromosome (HAC) has several advan-
tages as a gene therapy vector, including stable episomal 
maintenance that avoids insertional mutations and the 
ability to carry large gene inserts including the regula-
tory elements. Induced pluripotent stem (iPS) cells have 
great potential for gene therapy, as such cells can be 
generated from the individual’s own tissues, and when 
reintroduced can contribute to the specialized function 
of any tissue. As a proof of concept, we show herein 
the complete correction of a genetic deficiency in iPS 
cells derived from Duchenne muscular dystrophy (DMD) 
model (mdx) mice and a human DMD patient using a 
HAC  with  a  complete  genomic  dystrophin  sequence 
(DYS-HAC). Deletion or mutation of dystrophin in iPS 
cells  was  corrected  by  transferring  the  DYS-HAC  via 
microcell-mediated  chromosome  transfer  (MMCT). 
DMD patient- and mdx-specific iPS cells with the DYS-
HAC gave rise to differentiation of three germ layers in 
the  teratoma,  and  human  dystrophin  expression  was 
detected  in  muscle-like  tissues.  Furthermore,  chime-
ric mice from mdx-iPS (DYS-HAC) cells were produced 
and  DYS-HAC  was  detected  in  all  tissues  examined, 
with tissue-specific expression of dystrophin. Therefore, 
the combination of patient-specific iPS cells and HAC-
  containing defective genes represents a powerful tool 
for gene and cell therapies.
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IntroductIon
Embryonic stem (ES) cells have great potential for cell therapy 
against genetic disorders, as such cells can contribute to the spe-
cialized function of any tissue.1,2 However, one potential problem 
using ES cells to treat genetic disorders is host immunorejection 
of the transplanted cells. Although ES cells for gene therapy may 
be created for a patient using the nuclear transfer technique, many 
ethical concerns are associated with this practice.3,4 Conversely, 
induced pluripotent stem (iPS) cells can be generated from the 
  tissues of the individual with defined factors.5–7 Gene and cell 
therapies with iPS cells will thus offer advantages over nuclear 
transfer ES cell–mediated gene therapy with respect to ethical 
problems, as well as providing a genetic match with the patient 
and so decreasing the likelihood of immunorejection.
Homologous recombination has been used for the gene resto-
ration of various genetic defects in ES or iPS cells using one’s own 
genetic information.8,9 However, gene defects with unknown sites 
of mutation and those involving large deletions cannot be restored 
by homologous recombination.10 Duchenne muscular dystrophy 
(DMD) is caused by dysfunction of the dystrophin gene.11–15 As 
some  DMD  patients  show  a  large  deletion  in  the  DMD  gene, 
these defects cannot be restored by homologous recombination 
or exon-skipping approaches. Although several vectors have been 
developed for DMD gene therapy, no episomal vector containing 
the entire dystrophin genomic region has been reported, due to 
the extremely large size of this region (2.4 megabases).16 Human 
artificial chromosome (HAC) offers several advantages as gene 
therapy vector, including stable episomal maintenance that avoids 
insertional mutations and the ability to carry large gene inserts 
including  the  associated  regulatory  elements.17–23  We  therefore 
recently developed a HAC vector containing an entire dystrophin 
genome for DMD gene therapy.21 In this study, we established 
a  HAC-mediated  genomic  transfer  system  as  a  paradigm  for 
the treatment of a genetic disorder such as DMD by combining 
patient-derived iPS cells with a HAC vector containing the   normal 
version of a defective gene.
results
characterization of iPs cells from mdx mice
First, we attempted genetic correction of iPS cells derived from 
mdx mouse, as a model for DMD (Figure 1). The mdx-iPS cells 
were induced from mdx mouse embryonic fibroblasts by retro-
viral infection of the three factors including Klf4, Sox2, and Oct4. 
Transduced fibroblasts from the mdx mice gave rise to ES cell–
like  colonies,  and  these  colonies  were  isolated  based  on  mor-
phological criteria. Most mdx-iPS cells were positive for ES cell 
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markers, displayed a normal karyotype, and generated   teratoma 
and   chimeras (Supplementary Figure S1). Two randomly selected 
clones were used for the following experiments.
correction of mdx-iPs cells with dYs-HAc
We have previously developed a novel HAC vector containing full-
length genomic dystrophin, which was designated as DYS-HAC.21 
This DYS-HAC, which contains a visualization marker gene GFP 
and suicide gene TK, was transferred to the two independent mdx-
iPS clones via microcell-mediated chromosome transfer (MMCT). 
Eight GFP+ clones were selected and examined in the following 
experiments (Figure 2a). PCR analysis using primers for the detec-
tion of the DYS-HAC showed that six of the eight clones contained 
the  intact  dystrophin  region  in  the  HAC  (Figure  2b).  Reverse 
transcription  (RT)-PCR  analysis  showed  expression  of  dystro-
phin from the DYS-HAC was detected in six clones with the intact 
genomic dystrophin, whereas enhanced green fluorescent protein 
(EGFP) was expressed in all the clones examined (Figure 2d). 
Fluorescence in  situ hybridization (FISH) analyses showed that 
the DYS-HAC was present as an individual chromosome in the 
mdx-iPS cells (Figure 2c). These results show that the DYS-HAC 
can be transferred to mouse iPS cells at a comparable efficiency 
to that in mouse ES cells.21 To test the stemness of the iPS cells, 
RT-PCR analyses using primers for ES cell–specific genes were 
performed (Figure 2d). Endogenous Rex1, Nanog, Oct4, and Sox2 
were expressed in all mdx-iPS (DYS-HAC) cells, comparable to 
the parent mdx-iPS cells and Nanog-iPS cells   generated   previously 
with four Yamanaka’s factors, including c-Myc. Exogenous expres-
sions of Klf4, Sox2, and Oct4 in most mdx-iPS (DYS-HAC) cells 
were lower than those of parent mdx-iPS cells, suggesting that 
expression of transgenes was more or less silenced after MMCT.
To  determine  whether  the  mdx-iPS  (DYS-HAC)  cells  have 
the ability to differentiate into all three embryonic germ layers 
(endoderm, mesoderm, and ectoderm), cells were subcutaneously 
injected into nude mice. Transplanted mdx-iPS (DYS-HAC) gave 
rise to typical teratomas (n = 10), and GFP+ tissues were detected 
in these teratomas (Supplementary Figure S2a,b). Histological 
analyses  showed  that  tumors  contained  all  three  embryonic 
germ layers (Supplementary Figure S2c). FISH analyses showed 
that  DYS-HAC  was  detected  in  90%  of  cells  in  tumor  tissues 
(Supplementary  Figure  S2d).  Immunohistochemical  analyses 
detected the expression of human dystrophin in muscle-like tissues 
of teratomas derived from mdx-iPS (DYS-HAC) cells, but not in 
those derived from mdx-iPS cells (Figure 2e). These data suggest 
that loss of dystrophin expression in mdx-derived muscle tissue 
was restored by transferring the DYS-HAC into mdx-iPS cells.
expression in tissues from chimeric mice  
with dYs-HAc
In  order  to  determine  developmental  potential  and  expression 
of the transferred human dystrophin in various tissues, chimeric 
mice were produced from mdx-iPS (DYS-HAC) (Supplementary 
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Figure S2e). Chimeras with various forms of coat-color   chimerism 
were obtained, and GFP+ chimeric mice were used for the follow-
ing analyses. The EGFP gene driven by the CAG promoter on the 
DYS-HAC was expressed in all tissues examined (Figure 3a), sug-
gesting that DYS-HAC was stably maintained in vivo. To investi-
gate whether the tissue-specific isoform of the human dystrophin 
on the DYS-HAC was expressed, total RNAs from various tissues 
of the chimeras were analyzed by RT-PCR using three pairs of spe-
cific primers to detect human dystrophin tissue-specific transcripts. 
Isoforms Dp427I and Dp427m were expressed in chimeric heart 
and skeletal muscle, and Dp140 was expressed in chimeric brain, 
comparable to the human expression profile (Figure 3b). FISH anal-
yses showed that the DYS-HAC was detected in 50% of cells at least 
in the brain, liver, kidney, spleen, and skeletal muscle (Figure 3c). 
This detection correlated with coat-color   chimerism, and the DYS-
HAC was present as an individual chromosome in chimeric tail 
fibroblasts (Supplementary Figure S2e,f). Immunohistochemical 
analysis  using  a  human  dystrophin–  specific  antibody  showed 
human dystrophin   protein localized at the   sarcolemmal membrane 
in skeletal muscle (Figure 3d). These results suggest that isoforms 
of human dystrophin on the DYS-HAC were expressed in a tissue-
specific manner, and the human dystrophin protein was localized 
at the correct locus in iPS-derived chimeric skeletal muscle. These 
data were consistent with the results from our previous study using 
chimeric mice from normal mouse ES cells with the DYS-HAC.21
correction of dMd-iPs cells with dYs-HAc
Next, we attempted genetic correction of iPS cells derived from 
a DMD patient (Figure 1). We chose a DMD patient with dele-
tion of exons 4–43 for iPS cell induction because a large dele-
tion of this type cannot be corrected even using homologous 
recombination or other conventional vectors. The DYS-HAC was 
transferred to DMD patient–derived fibroblasts via MMCT, as we 
failed to directly transfer the HAC into human iPS or human ES 
cells due to the difficulty of cloning colonies derived from single 
cell following transfection or MMCT, which is an unsolved issue. 
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Figure 2  characterization of mdx-iPs with dYs-HAc. (a) Morphology of mdx-MEF, mdx-iPS, and mdx-iPS (DYS-HAC) cells. Phase-contrast (left 
panel) and GFP-fluorescence (right panel) micrographs are shown. (b) Genomic PCR analyses for detecting DYS-HAC in mdx-iPS cells. (c) FISH 
analyses for mdx-iPS (DYS-HAC) cells. An arrow indicates the DYS-HAC and the inset shows an enlarged image of the DYS-HAC. (d) RT-PCR analyses 
of ES cell–marker genes, four exogenous transcription factors, and human dystrophin. EGFP and Nat1 were used as internal controls. Primers for 
DYS 6L/6R, 7L/7R, and 8L/8R detected the isoform of dystrophin expressed in ES and iPS cells. (e) Immunohistochemical analyses of dystrophin in 
muscle-like tissues of each teratoma. Immunodetection of mouse and human dystrophin (left panel), immunodetection of human-specific dystrophin 
(middle panel), and GFP micrography (right panel) are shown. The insets show enlarged images of immunohistochemistry. Nanog-iPS- and mdx-iPS-
derived teratomas were used as positive and negative controls, respectively. CHO, Chinese hamster ovary; EGFP, enhanced green fluorescent protein; 
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The DYS-HAC was successfully transferred to DMD-fibroblasts, 
as shown by PCR and multiplex PCR analyses (Figure 4a and 
Supplementary  Figure  S3a).  FISH  analyses  showed  that  the 
DYS-HAC was present as an individual chromosome in DMD 
patient–derived fibroblasts (data not shown). The iPS cells were 
generated from the DMD-fibroblasts with the DYS-HAC using a 
combination of lenti  viral infection with mouse Slc7a1 and retro-
viral infection with KLF4, SOX2, OCT4, and c-MYC, as reported 
previously.6 Thirty GFP+ and human ES–like DMD-iPS (DYS-
HAC)  cells  derived  from  three  independent  DMD-fibroblast 
(DYS-HAC) clones were selected, and randomly selected nine 
clones were analyzed in the following experiments. To test the 
stemness of iPS cells, RT-PCR analyses using primers for ES cell–
specific genes were performed (Figure 4c). Endogenous REX1, 
NANOG, OCT4, and SOX2 were differentially expressed in iPS 
cells. Exogenous OCT4, KLF4, SOX2, and c-MYC were expressed 
in  some  iPS  cells.  These  findings  show  that  DMD-iPS  (DYS-
HAC) cells were comparable to DMD-iPS and normal human 
iPS cells. PCR and multiplex PCR analyses showed that the DYS-
HAC was maintained in all examined iPS cells, comparable to 
parent  DMD-fibroblast  (DYS-HAC)  clones  (Supplementary 
Figure S3a,b). FISH analyses showed that the DYS-HAC was 
present as an individual chromosome in the DMD-iPS (DYS-
HAC) cells (Figure 4d). To examine mitotic stability of the DYS-
HAC in DMD-iPS (DYS-HAC) cells, iPS cells were cultured for 
about 4 months without selection. FISH analyses revealed that 
the  DYS-HAC  was  independently  and  stably  maintained  in 
DMD-iPS (DYS-HAC) cells (Figure 4e). These data suggest that 
the DYS-HAC could be maintained stably during iPS generation 
and even after long-term culture in vitro.
To  determine  whether  DMD-iPS  (DYS-HAC)  cells  could 
differentiate  into  all  three  embryonic  germ  layers,  cells  were 
injected into testes of severe combined immunodeficiency mice. 
Transplanted DMD-iPS (DYS-HAC) gave rise to typical terato-
mas (n = 12), and GFP+ tissues were detected in these teratomas 
(Supplementary Figure S4a). Histological analyses revealed all 
three embryonic germ layers in all teratomas (Supplementary 
Figure  S4b).  FISH  analyses  showed  that  the  DYS-HAC  was 
detected  in  90%  of  cells  in  tumor  tissues  (Supplementary 
Figure S4c). Immunohistochemical analysis showed expression 
of human dystrophin in muscle-like tissues of teratomas derived 
from DMD-iPS (DYS-HAC) cells, but not in those derived from 
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DMD-iPS cells (Figure 4f). These data were comparable to the 
results of the mdx-iPS (DYS-HAC) experiments mentioned above. 
These data suggest that loss of dystrophin expression in DMD-
derived muscle tissue was restored by transferring the DYS-HAC 
into DMD-iPS cells.
dIscussIon
Previously, mouse iPS cells derived from sickle cell anemia have 
been corrected using the homologous recombination approach, 
with  the  model  mice  treated  using  iPS-derived  hematopoietic 
progenitors.9 Most recently, Fanconi anemia patient–derived iPS 
cells were corrected using the viral vector, and the iPS cells could 
give rise to hematopoietic progenitors of the myeloid and eryth-
roid lineages, showing the correction of the disease phenotype.24 
However, genetic restoration by the homologous recombination 
and gene transfer using the conventional vectors, including viral 
and plasmid vector, cannot be applied in DMD patients with large 
deletions in the gene. The present results have shown the first 
complete genetic correction of a human genetic disorder, DMD 
with deletion of exon 4–43, using a novel HAC as an episomal 
vector. As Kimura et al. recently reported myogenic conversion 
from fibroblasts by transducing the inducible myogenic regulator, 
MyoD, the DMD-fibroblast (DYS-HAC) developed in this study 
may also represent a source for gene therapy.25
To the best of our knowledge, iPS cells have been generated 
from human primary fibroblast populations, but not from cloned 
cells.6 In this study, we could generate patient-derived genetically 
corrected  iPS  cells  even  from  fibroblasts  cloned  after  MMCT. 
Although several dystrophin isoforms cannot be expressed using 
previously reported vector systems, our HAC vector system con-
taining an entire genomic dystrophin enabled isoform expres-
sions  in  iPS-derived  various  tissues  with  the  DYS-HAC  in  a 
tissue-  specific manner. As the integrating viral vectors were used 
for iPS generation in this study, however, iPS induction using a 
nonintegrating  vector  system,  protein  introduction  system,  or 
chemical small molecules may be needed for safe gene therapy.26–33 
The HAC vector may also be a promising tool for safe iPS genera-
tion: the HAC is a nonintegrating vector, and the elimination of 
a HAC, with a conditional centromere, from the cells can also be 
performed.34
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In the MMCT methods, it is possible that host chromosomes 
(e.g., A9 and CHO) can be transferred along with the HAC at 
once. However, we have seldom observed the co-transfer of host 
chromosomes during MMCT (~1/100 clones). In this study, host 
chromosomes  were  not  detected  in  mdx-iPS  cells  and  DMD-
fibroblasts after MMCT (data not shown).
Furthermore, advances in efficient methods for differentia-
tion and purification of stem cells, including ES and iPS cells, 
are anticipated. Barberi et al. reported engraftable skeletal myo-
blasts from human ES cells.35 Darabi et  al. also reported the 
generation of functional skeletal muscle from mouse ES cells 
by induction of Pax3 and the treatment of mdx mice using ES 
cell–derived cells.36 Application of these methods to iPS cells 
combined with our HAC vector system may open a way to more 
sophisticated DMD gene therapies. Taken together, genetic cor-
rection of patient-specific iPS cells by MMCT of the DYS-HAC, 
efficient  differentiation  from  iPS  cells  into  muscle  stem  cells 
in vitro, and transplantation of genetically corrected autologous 
cells into the same patient are needed for the gene therapy of 
DMD (Figure 1). Thus, stem cells derived from multiple poten-
tial sources combined with HAC-mediated gene delivery should 
allow safe treatment of various genetic defects, with elegant dif-
ferentiation technology to come.
MAterIAls And MetHods
Cell culture. Fibroblasts from a DMD patient (GM05169) containing dele-
tion of exons 4–43 in the dystrophin gene were obtained from Coriell 
Institute (Camden, NJ). Fibroblast cells were grown in α-MEM plus 15% 
fetal bovine serum (FBS) and 2 mmol/l L-glutamine. DMD model mice 
(mdx) were obtained from Charles River (Yokohama, Japan), and mouse 
embryonic fibroblasts (MEFs) were isolated from 13.5 days postcoitum 
embryos. The mdx-MEF and PLAT-E cells were grown in Dulbecco’s modi-
fied Eagle’s medium (Sigma, St Louis, MO) plus 10% FBS. Chinese hamster 
ovary (CHO) or A9 cells containing the DYS-HAC were constructed as pre-
viously described.21 The CHO (DYS-HAC) cells were maintained in Ham’s 
F-12 nutrient mixture (Invitrogen, Carlsbad, CA) plus 10% FBS with 8 µg/
ml blasticidin S hydrochloride (Funakoshi, Tokyo, Japan). The A9 (DYS-
HAC) cells were maintained in Dulbecco’s modified Eagle’s medium plus 
10% FBS with 4 µg/ml blasticidin S hydrochloride. The parental mdx-iPS 
cell line and microcell hybrid clones, mdx-iPS (DYS-HAC), were main-
tained  on  mitomycin  C  (Sigma)–treated  Jcl:ICR  (CLEA  Japan,  Tokyo, 
Japan) MEFs as feeder layers in Dulbecco’s modified Eagle’s medium with 
18% FBS (Thermo Scientific HyClone, Yokohama, Japan), 1 mmol/l sodium 
pyruvate (Invitrogen), 0.1 mmol/l nonessential amino acids (Invitrogen), 
0.1 mmol/l 2-mercaptoethanol (Sigma), 2 mmol/l L-glutamine (Invitrogen), 
and  1,000 U/ml  leukemia  inhibitory  factor  (Funakoshi).  Human  iPS 
cells were maintained on SNL (STO) feeder cells in primate ES medium 
(ReproCell, Tokyo, Japan) supplemented with 4 ng/ml recombinant basic 
fibroblast growth factor (Wako, Osaka, Japan). Mouse and human iPS cells 
were maintained as described previously.5,6 The control iPS cell line, Nanog-
iPS (APS0001, iPS-MEF-Ng-20D-17), was obtained from the RIKEN BRC 
Cell Bank (Tsukuba, Japan). The SNL cell line for feeder layer was obtained 
from the SANGER Institute (Cambridge, UK).
Generation  of  iPS  cells.  Generation  of  iPS  cells  from  mdx-MEFs  was 
performed using a retroviral system as described previously.5 Briefly, ret-
roviruses were generated with Plat-E packaging cells. Three retroviruses 
containing Oct4, Klf4, and Sox2, were infected into mdx-MEFs. Four days 
after transfection, mdx-MEFs were replated at 3.5 × 105 cells per 100-cm 
dish on MEF feeder cells. The next day, medium was replaced with mouse 
ES cell medium. Thirteen days after infection, mouse ES–like colonies 
were selected up to the MEF feeder cells on 24-well plates. Generation of 
iPS cells from human DMD-fibroblasts was performed using the retrovi-
rus system combined with the lentivirus system as described previously.6 
Briefly, lentivirus production for Slc7a1 expression was performed using 
293T cells, and lentivirus was infected into human fibroblasts. Four ret-
roviruses containing OCT4, KLF4, SOX2 and c-MYC were infected into 
Slc7al-expressing human DMD-fibroblasts. The four retroviral expression 
vectors were obtained from Addgene (Cambridge, MA). Six days after 
transfection, fibroblasts were replated at 5 × 104 cells per 100-cm dish on 
SNL feeder cells. The next day, medium was replaced with primate ES cell 
medium supplemented with 4 ng/ml basic fibroblast growth factor. Thirty 
days after transduction, human ES–like colonies were selected up to the 
SNL feeder cells on 24-well plates.
MMCT. MMCT was performed as described previously.37 CHO or A9 cells 
containing the DYS-HAC were used as donor microcell hybrids. Briefly, 
mdx-iPS and DMD-fibroblast cells were fused with microcells prepared 
from donor hybrid CHO (DYS-HAC) or A9 (DYS-HAC) cells, and selected 
with blasticidin S (3 µg/ml). The transferred DYS-HAC in each line was 
characterized by PCR, RT-PCR, and FISH analyses.
Genomic  PCR  analyses. Genomic DNA was extracted from cell lines 
and chimeric tissue specimens using a genomic extraction kit (Gentra 
Systems, Minneapolis, MN), and PCR was performed using primers as 
follows. Primer pairs for the detection of the region of human dystro-
phin gene were as follows: DYS3L/3R [163 base pairs (bp)], 5′-AACAACT 
GAACAGCCGGTGGA-3′ a n d  5 ′-GGGGTGGTGGGTTGGATTTT-3′; 
DYS4L/4R (128 bp), 5′-GCAAGAGCAACAAAGTGGCCTA-3′ and 5′-AG 
CTTCTTCCAGCGTCCCTCA-3′; DYS5L/5R (132 bp), 5′-ACCTTCAG 
AACCGGAGGCAAC-3′ and 5′-AGGGACCCTCCTTCCATGACTC-3′; 
DYS6L/6R (170 bp), 5′-TGGAACGCATTTTGGGTTGTT-3′ and 5′-AA 
AACAATGCGCTGCCTCAAA-3′;  DYS7L/7R  (151 bp),  5′-TTTGCAT 
CCTTTTGGCGTGAT-3′ a n d  5 ′-AAACTCAAGCCTGCCCCACTC-3′; 
DYS8L/8R (155 bp), 5′-GCTGCTAGCAATGCCACGATT-3′ and 5′-GGA 
TGGGCTGGGAATCCATAG-3′.  Primer  pairs  for  detection  of  EGFP 
on the HAC, mouse genome (A9), and hamster genome (CHO) were as 
follows:  EGFPL/R  (479 bp),  5′-CCTGAAGTTCATCTGCACCA-3′  and 
5′-TGCTCAGGTAGTGGTTGTCG-3′; Cyp3a13-5L/6R (239 bp), 5′-GC 
TCAGCAGGCTCAGCCCTGA-3′ and 5′-TCCAAGCCAGTAAAGGAA
AGAATTAT-3′; Furin-L/R, 5′-ACTCAGAGATCCACTGCACCAGGAT
CCAAGGGAGG-3′ a n d  5 ′-GCTCGAGCGGCTACACCACAGACACC
ATTGTTGGCTACTGCTGCC-3′. Multiplex PCR analyses to detect the 
deletion of exons within human dystrophin were performed in accordance 
with the protocols of the manufacturer (Maxim Biotech, San Francisco, 
CA). CHO (DYS-HAC), A9 (DYS-HAC), HFL1, and HFL1-iPS were used 
as positive controls. mdx-iPS, DMD-fibroblasts, DMD-iPS, STO, CHO, 
and A9 cells were used as negative controls.
FISH analyses. FISH analyses were performed using either fixed meta-
phase or interphase spreads of each cell hybrid using digoxigenin-labeled 
(Roche, Basel, Switzerland) human COT-1 DNA (Invitrogen) and biotin-
labeled  BAC  DNA  (RP11-954B16,  located  in  the  dystrophin  genomic 
region),  essentially  as  described  previously.37  Chromosomal  DNA  was 
counterstained with DAPI (Sigma). Images were captured using the NIS-
Elements system (Nikon, Tokyo, Japan).
RT-PCR analyses. Total RNA from chimeric tissue specimens was prepared 
using ISOGEN (Nippon Gene, Tokyo, Japan) and purified using RNeasy 
columns (Qiagen, Hilden, Germany), in accordance with the manufactur-
er’s instructions, and was then treated with RNase-free DNase I (Wako). 
First-strand complementary DNA (cDNA) synthesis was performed using 
random hexamers and SuperScript III reverse transcriptase (Invitrogen). 
EGFP and GAPDH  were  used  as  internal  controls.  Human  cDNA  was 
used as a positive control, whereas cDNA and DNA from C57BL/6 mouse 392  www.moleculartherapy.org  vol. 18 no. 2 feb. 2010     
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tissues were used as negative controls. Total RNA from cultured cells was 
  purified with Trizol reagent (Invitrogen) and treated with a Turbo DNA-
free kit (Ambion/Applied Biosystems, Tokyo, Japan) to remove genomic 
DNA contamination. First-strand cDNA synthesis was undertaken using 
an  oligo-(dT)20  primer  and  ReverTraAce-α  (Toyobo,  Osaka,  Japan).  In 
analyses of mouse iPS cells, Nanog-iPS and mouse ES (TT2) cells were 
used as positive controls, whereas mdx-MEF was used as a negative con-
trol. Nat1 was used as an internal control. In analyses of human iPS cells, 
DMD-fibroblasts were used as negative controls. Nat1 was used as an inter-
nal control. PCR was performed with cDNA using ExTaq (Takara Bio, Otsu, 
Japan) or AmpliTaq Gold (PerkinElmer, Waltham, MA). Amplifications 
were performed with an annealing temperature of 58 °C for 30–35 cycles, 
then amplified fragments were resolved by electrophoresis on a 2% aga-
rose gel, followed by staining with ethidium bromide. Primer sequences 
were  as  follows:  for  the  dystrophin  isoform  Dp427m,  DYS  427me1L/
DYS427me1R (211 bp), 5′-TTCCCCCTACAGGACTCAGA-3′ and 5′-TCTT 
CCCACCAAAGCATTTT-3′; for dystrophin isoform Dp427I, DYS427le1L/
DYSe3R  (150 bp),  5′-CTCATGATGAAAGAGAAGATGTTCAA-3′  and 
5′-CTGTCAGGCCTTCGAGGA-3′;  for  dystrophin  isoform  Dp140,  DYS   
140e1L/DYS e45R (189 bp), 5′-TGCTGGCTGCTCTGAACTAA-3′ and   
5′-GGCTTCCCAATTTTTCCTGT-3′;  for  EGFP,  EGFPL/R  (479 bp),   
5′-CCTGAAGTTCATCTGCACCA-3′ a n d  5 ′-TGCTCAGGTAGTGGTT 
GTCG; for GAPDH (mouse and human), RPC1/2, 5′-CCATCTTCCAG 
GAGCGAGA-3′ and 5′-TGTCATACCAGGAAATGAGC-3′. Primers for 
DYS6L/6R, DYS7L/7R, and DYS8L/8R were the same as in genomic PCR 
  analyses. RT-PCR to detect endogenous ES markers and exogenous trans-
genes  were  performed  using  primers  as  described  previously.5,6  Primer 
pairs for the detection of transgenes of cMYC and SOX 2 were as follows: 
hMYC-S3148/pMXs-AS3095,  5′-CAGAGGAGGAACGAGCTAAAAC-3′ 
and  5′-AGACCAACTGGTAATGGTAGCG-3′;  hSOX2-S691/pMXs- 
AS3206, 5′-GGCACCCCTGGCATGGCTCTTGGCTC-3′ and 5′-TTATC 
GTCGACCACTGTGCTGGCG-3′.
Generation of chimeric mice. Chimeric mice were produced from the two 
mdx-iPS and three mdx-iPS (DYS-HAC) cell lines. Chimera production 
was performed as described previously.37 Briefly, iPS cells were injected 
into blastocyst-stage embryos derived from ICR mice (CLEA Japan) and 
then transferred into pseudopregnant ICR females. Three chimeric mice 
showing 50% coat-color chimerism were used for expression analyses in 
various tissues. All chimeric mice used for analyses were 1–4 weeks old. All 
animal experiments were approved by the Institutional Animal Care and 
Use Committee of Tottori University.
Teratoma  formation  and  histology.  To  produce  teratomas,  2  ×  106 
mdx-iPS (DYS-HAC), mdx-iPS, and mdx-fibroblast cells were subcu-
taneously injected into CD-1 (ICR)-nu mice (Charles River), and 1 × 
106 DMD-iPS (DYS-HAC), DMD-iPS, and DMD-fibroblast (DYS-HAC) 
cells were injected into testes of severe combined immunodeficiency 
mice (Charles River). After 5–6 weeks in the mdx-iPS series and 9–13 
weeks in the DMD-iPS series, resected teratomas were fixed in 20% for-
malin and processed for paraffin sectioning, then stained with hema-
toxylin and eosin.
Immunohistochemical analyses. Formalin-fixed and paraffin-embedded 
specimens and OCT (optimal cutting temperature) compound–embedded 
frozen specimens were used for immunohistochemistry. Primary antibod-
ies used in this study were as follows: rabbit polyclonal antibody against 
both human and mouse dystrophin (1:100; Lab Vision, Fremont, CA); and 
mouse monoclonal antibody against human dystrophin (MANDYS106, 
diluted 1:4; a gift from Glenn E. Morris, Keele University, Shropshire, UK). 
Immunoreaction was developed by using the SAB (streptavidin–biotin) 
peroxidase complex method with the Histofine SAB-PO Kit (Nichirei, 
Tokyo, Japan) for rabbit polyclonal antibody and the Histofine Mouse Stain 
Kit (Nichirei) for mouse monoclonal antibody, or visualized with Alexa 
Fluor 555 goat anti-mouse conjugate (diluted 1:1,000; Molecular Probes, 
Eugene, OR).
suPPleMentArY MAterIAl
Figure S1.  Characterisation of mdx-iPS.
Figure  S2. Histological  and  FISH  analyses  in  mdx-iPS  (DYS-HAC)-
derived teratoma and chimera.
Figure S3. Genomic PCR analyses in DMD-fibroblast (DYS-HAC) and 
DMD-iPS (DYS-HAC) cells.
Figure  S4. Histological and FISH analyses in DMD-iPS (DYS-HAC)-
derived teratoma.
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